Literature DB >> 15713142

Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety.

Andrew Shennan1, Griff Jones, Jennifer Hawken, Sarah Crawshaw, Jeanette Judah, Victoria Senior, Theresa Marteau, Susan Chinn, Lucilla Poston.   

Abstract

OBJECTIVE: To assess efficacy of cervico-vaginal fetal fibronectin as a predictor of spontaneous preterm birth in a high risk antenatal population, and to evaluate the psychological impact of fetal fibronectin testing.
DESIGN: An observational study.
SETTING: The antenatal clinic at a tertiary referral hospital. POPULATION: One hundred and forty-six pregnant women with known risk factors for spontaneous preterm birth.
METHODS: Women designated as 'at risk' for preterm delivery by clinical history were screened for fetal fibronectin at 24 and again at 27 weeks of gestation. Anxiety levels were assessed by questionnaire and compared with anxiety levels of 206 low risk women also tested for fetal fibronectin. Fetal fibronectin results were disclosed to the woman and her clinician. MAIN OUTCOME MEASURES: Maternal anxiety and efficacy of the 24-week fetal fibronectin test to predict delivery before 30, 34 and 37 weeks of gestation.
RESULTS: Maternal anxiety was higher pretesting in those at high risk compared with low risk women undergoing the test. Among the high risk women, anxiety was raised to clinically significant levels in those receiving a positive fetal fibronectin screening test result. In all women, 5%, 9% and 21% delivered <30, <34 or <37 weeks of gestation, respectively. Nine percent (n= 13) tested positive for fetal fibronectin at 24 weeks. Predictive power for fetal fibronectin (24 weeks) was greatest for delivery <30 weeks of gestation, with a likelihood ratio of 15 for a positive test (6/13 positive women delivered before 30 weeks).
CONCLUSIONS: Fetal fibronectin was most efficient as a predictor of preterm spontaneous delivery <30 weeks of gestation, but was associated with high levels of anxiety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713142     DOI: 10.1111/j.1471-0528.2004.00420.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  8 in total

Review 1.  The management of preterm labour.

Authors:  Jayanta Chatterjee; Joanna Gullam; Manu Vatish; Steve Thornton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

2.  The use of fetal fibronectin testing in the management of a triplet pregnancy with a short cervix.

Authors:  Alexandra Karin Morriss; Elizabeth Smout; Andrew Shennan
Journal:  BMJ Case Rep       Date:  2011-07-27

3.  Quantitative fetal fibronectin to predict spontaneous preterm birth: a review.

Authors:  Natasha L Hezelgrave; Andrew H Shennan
Journal:  Womens Health (Lond)       Date:  2015-12-11

4.  Development and validation of a transcriptomic signature-based model as the predictive, preventive, and personalized medical strategy for preterm birth within 7 days in threatened preterm labor women.

Authors:  Yuxin Ran; Jie He; Wei Peng; Zheng Liu; Youwen Mei; Yunqian Zhou; Nanlin Yin; Hongbo Qi
Journal:  EPMA J       Date:  2022-01-18       Impact factor: 6.543

Review 5.  Additional effects of the cervical length measurement in women with preterm contractions: a systematic review.

Authors:  Jolande Y Vis; Rosanna A Kuin; William A Grobman; Ben Willem J Mol; Patrick M M Bossuyt; Brent C Opmeer
Journal:  Arch Gynecol Obstet       Date:  2011-04-12       Impact factor: 2.344

6.  Trial protocol OPPTIMUM-- does progesterone prophylaxis for the prevention of preterm labour improve outcome?

Authors:  Jane E Norman; Andrew Shennan; Phillip Bennett; Steven Thornton; Stephen Robson; Neil Marlow; John Norrie; Stavros Petrou; Neil Sebire; Tina Lavender; Sonia Whyte
Journal:  BMC Pregnancy Childbirth       Date:  2012-08-06       Impact factor: 3.007

7.  The influence of medical testing on patients' health: an overview from the gynecologists' perspective.

Authors:  Jolande Y Vis; Myra C B van Zwieten; Patrick M M Bossuyt; Karel G M Moons; Marcel G W Dijkgraaf; Kirsten J McCaffery; Ben Willem J Mol; Brent C Opmeer
Journal:  BMC Med Inform Decis Mak       Date:  2013-10-10       Impact factor: 2.796

8.  Women's perspectives of the fetal fibronectin testing process: a qualitative descriptive study.

Authors:  Wendy E Peterson; Ann E Sprague; Jessica Reszel; Mark Walker; Deshayne B Fell; Sherry L Perkins; Sandra I Dunn; Moya Johnson
Journal:  BMC Pregnancy Childbirth       Date:  2014-06-04       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.